Literature DB >> 6469933

Naltrexone: a clinical perspective.

R A Greenstein, I C Arndt, A T McLellan, C P O'Brien, B Evans.   

Abstract

The narcotic antagonist naltrexone was studied in over 300 opiate addicts. Patient selection was a major factor in determining retention and treatment outcome. Treatment time ranged from 1 week to over a year (mean = 2 months). A quarter of the study patients had multiple treatment episodes. Stabilized patients had few side effects, except for occasional nausea and abdominal cramps. Almost half the subjects tested naltrexone by using opiates at least once; all reported satisfactory narcotic blockade. Very few subjects switched to nonopiates to get high, although several did increase their alcohol consumption during the first weeks of therapy. One-third of subjects contacted in a follow-up study were opiate-free 6 months after stopping naltrexone, indicating a successful short-term treatment modality.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469933

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

Review 2.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

Review 4.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

Review 5.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

Review 6.  Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

7.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

Review 8.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.